Abstract
We conducted a national multicenter randomized clinical trial to compare the efficacy of a novel anti-infective central venous catheter (CVC) coated with 5-fluorouracil (5-FU) (Angiotech Pharmaceuticals, Vancouver, Canada) with a catheter coated with chlorhexidine and silver sulfadiazine (CH-SS) (ARROWgard Blue; Arrow International, Inc., Reading, PA, USA) in preventing catheter colonization, local site infection and catheter-related bloodstream infection (CRBSI).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.